CO2020006395A2 - Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular - Google Patents
Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscularInfo
- Publication number
- CO2020006395A2 CO2020006395A2 CONC2020/0006395A CO2020006395A CO2020006395A2 CO 2020006395 A2 CO2020006395 A2 CO 2020006395A2 CO 2020006395 A CO2020006395 A CO 2020006395A CO 2020006395 A2 CO2020006395 A2 CO 2020006395A2
- Authority
- CO
- Colombia
- Prior art keywords
- muscular dystrophy
- edasalonexent
- treatment
- dosage regimen
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La invención proporciona métodos y composiciones para el tratamiento de una distrofia muscular, por ejemplo, distrofia muscular de Duchenne (DMD), en un sujeto, con un salicilato acetilado de ácido graso, por ejemplo, edasalonexent, efectivo para alcanzar un umbral de concentración plasmática del salicilato acetilado de ácido graso en el sujeto, por ejemplo, un umbral de concentración plasmática de al menos alrededor de 20 ng/ml durante al menos 12 horas en un periodo de 24 horas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762581981P | 2017-11-06 | 2017-11-06 | |
| PCT/US2018/059283 WO2019090271A1 (en) | 2017-11-06 | 2018-11-05 | Edasalonexent dosing regimen for treating muscular dystrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020006395A2 true CO2020006395A2 (es) | 2020-06-09 |
Family
ID=66332350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0006395A CO2020006395A2 (es) | 2017-11-06 | 2020-05-27 | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210023029A1 (es) |
| EP (1) | EP3706730A4 (es) |
| JP (1) | JP2021502328A (es) |
| KR (1) | KR20200084877A (es) |
| CN (1) | CN111315372A (es) |
| AU (1) | AU2018359969A1 (es) |
| BR (1) | BR112020009020A2 (es) |
| CA (1) | CA3078727A1 (es) |
| CL (1) | CL2020001180A1 (es) |
| CO (1) | CO2020006395A2 (es) |
| IL (1) | IL274375A (es) |
| MX (1) | MX2020004659A (es) |
| PH (1) | PH12020550526A1 (es) |
| RU (1) | RU2020118258A (es) |
| SG (1) | SG11202004115WA (es) |
| WO (1) | WO2019090271A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020191087A1 (en) * | 2019-03-18 | 2020-09-24 | Ptc Therapeutics, Inc. | Therapeutic combinations for use in treating a muscular dystrophy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2315740T3 (pl) * | 2008-07-08 | 2018-05-30 | Catabasis Pharmaceuticals, Inc. | Salicylany acetylowane kwasem tłuszczowym i ich zastosowania |
| PT2519230T (pt) * | 2009-12-31 | 2019-01-18 | Marius Pharmaceuticals Llc | Modulação de solubilidade, estabilidade, absorção, metabolismo e perfil farmacocinético de fármacos lipofílicos por esteróis |
| US20110172240A1 (en) * | 2010-01-08 | 2011-07-14 | Milne Jill C | Fatty acid fumarate derivatives and their uses |
-
2018
- 2018-11-05 WO PCT/US2018/059283 patent/WO2019090271A1/en active Application Filing
- 2018-11-05 JP JP2020520142A patent/JP2021502328A/ja active Pending
- 2018-11-05 BR BR112020009020-4A patent/BR112020009020A2/pt not_active Application Discontinuation
- 2018-11-05 US US16/761,783 patent/US20210023029A1/en not_active Abandoned
- 2018-11-05 SG SG11202004115WA patent/SG11202004115WA/en unknown
- 2018-11-05 RU RU2020118258A patent/RU2020118258A/ru unknown
- 2018-11-05 CN CN201880071203.6A patent/CN111315372A/zh active Pending
- 2018-11-05 MX MX2020004659A patent/MX2020004659A/es unknown
- 2018-11-05 KR KR1020207015893A patent/KR20200084877A/ko unknown
- 2018-11-05 AU AU2018359969A patent/AU2018359969A1/en not_active Abandoned
- 2018-11-05 EP EP18874489.0A patent/EP3706730A4/en not_active Withdrawn
- 2018-11-05 CA CA3078727A patent/CA3078727A1/en not_active Abandoned
-
2020
- 2020-04-30 PH PH12020550526A patent/PH12020550526A1/en unknown
- 2020-04-30 IL IL274375A patent/IL274375A/en unknown
- 2020-05-05 CL CL2020001180A patent/CL2020001180A1/es unknown
- 2020-05-27 CO CONC2020/0006395A patent/CO2020006395A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020004659A (es) | 2020-10-14 |
| SG11202004115WA (en) | 2020-06-29 |
| PH12020550526A1 (en) | 2021-05-10 |
| WO2019090271A1 (en) | 2019-05-09 |
| AU2018359969A1 (en) | 2020-05-14 |
| RU2020118258A (ru) | 2021-12-08 |
| US20210023029A1 (en) | 2021-01-28 |
| CL2020001180A1 (es) | 2020-09-25 |
| CN111315372A (zh) | 2020-06-19 |
| CA3078727A1 (en) | 2019-05-09 |
| EP3706730A4 (en) | 2021-08-11 |
| KR20200084877A (ko) | 2020-07-13 |
| BR112020009020A2 (pt) | 2020-10-27 |
| EP3706730A1 (en) | 2020-09-16 |
| JP2021502328A (ja) | 2021-01-28 |
| IL274375A (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| CL2017003006A1 (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
| EA201891199A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| EA201891200A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| CL2017003005A1 (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| EA201890048A1 (ru) | Композиции, содержащие бактериальные штаммы | |
| CO2018003134A2 (es) | Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2017002031A1 (es) | Formulación en polvo nasal para el tratamiento de hipoglicemia | |
| EA201890811A1 (ru) | Способы лечения мышечной дистрофии | |
| GT201700132A (es) | Compuestos de isoxazol de ácido hidroxámico como inhibidores de lpxc | |
| EA201490688A1 (ru) | 2-тиопиримидиноны | |
| EA202191513A1 (ru) | Снижение вязкости фармацевтических составов | |
| MY187945A (en) | Improved mouthwash preparation | |
| CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
| MX2019002190A (es) | Uso de pridopidina para tratar distonías. | |
| CL2016002879A1 (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
| CL2017000118A1 (es) | Métodos y composiciones para tratar desórdenes relacionados con el vih | |
| CL2020001358A1 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
| CO2020006395A2 (es) | Régimen de dosificación de edasalonexent para el tratamiento de distrofia muscular |